Philipp Ianevski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philipp Ianevski has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Ianevski
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
3 shared publications - Kristen Nader
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
2 shared publications - Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
2 shared publications - Aleksandra Adamska
Lund University 1 Division of Translational Cancer Research, Department of Laboratory Medicine Lund, Sweden
1 shared publication - Anna Cichońska
Harmonic Discovery Inc
1 shared publication - Aurélie Baudet
Lund University 4 Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center/Stem Therapy, Department of Laboratory Medicine Lund, Sweden
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Combined ATR and Mitotic Inhibition Is Effective against MYCN -Amplified Neuroblastoma
High-risk neuroblastoma is an aggressive pediatric malignancy characterized by a high proliferative capacity, intrinsic replication stress, and poor clinical outcomes. Although mitotic inhibitors show preclinical efficacy, their clinical use is limited by dose-dependent toxicity. In this study, we performed high-throughput combinatorial drug screening using MYCN-amplified (MNA) human neuroblastoma tumoroids to identify drugs with orthogonal mechanisms that synergize with low-dose mitotic inhibition. Promising drug combinations were prioritized using a multifactorial approach including dose–response matrices across multiple neuroblastoma tumoroids and CD34+ cord blood cells, synergy area scores, and machine learning–based response predictions. Several therapeutic classes were selected, including kinase inhibitors, differentiation agents, and hormone therapies. Notably, combined ataxia telangiectasia and Rad 3–related (ATR) inhibition by elimusertib and mitotic kinesin spindle protein (KSP) inhibition showed additive to mild synergy and induced neuroblastoma cell death. This combination reduced tumor growth and prolonged survival in neuroblastoma MNA, chemoresistant patient-derived xenografts. Furthermore, alternating dosing schedules were well tolerated and maintained stable disease control in vivo. Collectively, these findings establish combined ATR and low-dose mitotic inhibition as a promising therapeutic strategy for MNA neuroblastoma.
- 9 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Open AccessCombined ATR and Mitotic Inhibition Is Effective against MYCN -Amplified Neuroblastoma
High-risk neuroblastoma is an aggressive pediatric malignancy characterized by a high proliferative capacity, intrinsic replication stress, and poor clinical outcomes. Although mitotic inhibitors show preclinical efficacy, their clinical use is limited by dose-dependent toxicity. In this study, we performed high-throughput combinatorial drug screening using MYCN-amplified (MNA) human neuroblastoma tumoroids to identify drugs with orthogonal mechanisms that synergize with low-dose mitotic inhibition. Promising drug combinations were prioritized using a multifactorial approach including dose–response matrices across multiple neuroblastoma tumoroids and CD34+ cord blood cells, synergy area scores, and machine learning–based response predictions. Several therapeutic classes were selected, including kinase inhibitors, differentiation agents, and hormone therapies. Notably, combined ataxia telangiectasia and Rad 3–related (ATR) inhibition by elimusertib and mitotic kinesin spindle protein (KSP) inhibition showed additive to mild synergy and induced neuroblastoma cell death. This combination reduced tumor growth and prolonged survival in neuroblastoma MNA, chemoresistant patient-derived xenografts. Furthermore, alternating dosing schedules were well tolerated and maintained stable disease control in vivo. Collectively, these findings establish combined ATR and low-dose mitotic inhibition as a promising therapeutic strategy for MNA neuroblastoma.
- Open Access
Improving reproducibility in pharmacogenomic screens through cross-study benchmarking
Drug-response measurements across pre-clinical pharmacogenomic studies remain poorly correlated, which limits biomarker discovery, precision oncology, and predictive modelling. The drivers of this inconsistency have been debated but not yet resolved. By integrating 15 pharmacogenomic studies encompassing 760 small-molecule compounds, 1,111 cell models, and 9.8 million dose-response measurements, we demonstrate that dose-response metric is the strongest driver of inconsistency, followed by experimental factors, such as treatment duration, plate format, and viability readout; in contrast, cell line molecular features contribute only minimally to reproducibility. Among drug classes, hormone therapies and PARP inhibitors show the highest concordance, whereas antimetabolites, topoisomerase inhibitors, and mitotic inhibitors exhibit substantial response variability across studies. To improve consistency, we developed a Drug Response Score (DRS), a proximity-weighted measure that emphasize pharmacologically informative concentrations near IC 50 , and we demonstrate in systematic benchmarking how DRS markedly improved cross-dataset concordance. Applications to patient-derived neuroblastoma organoids and leukemia patients’ primary cells demonstrate that DRS improves replicate-level consistency in patients’ drug-response profiles. To improve reproducible pharmacogenomic studies, we make openly available an integrated Drug Response Resource (iDRR, https://aittokallio.group/iDRR/ ), a standardized 15-dataset portal that supports robust biomarker discovery and cross-study benchmarking.
Open AccessImproving reproducibility in pharmacogenomic screens through cross-study benchmarking
Drug-response measurements across pre-clinical pharmacogenomic studies remain poorly correlated, which limits biomarker discovery, precision oncology, and predictive modelling. The drivers of this inconsistency have been debated but not yet resolved. By integrating 15 pharmacogenomic studies encompassing 760 small-molecule compounds, 1,111 cell models, and 9.8 million dose-response measurements, we demonstrate that dose-response metric is the strongest driver of inconsistency, followed by experimental factors, such as treatment duration, plate format, and viability readout; in contrast, cell line molecular features contribute only minimally to reproducibility. Among drug classes, hormone therapies and PARP inhibitors show the highest concordance, whereas antimetabolites, topoisomerase inhibitors, and mitotic inhibitors exhibit substantial response variability across studies. To improve consistency, we developed a Drug Response Score (DRS), a proximity-weighted measure that emphasize pharmacologically informative concentrations near IC 50 , and we demonstrate in systematic benchmarking how DRS markedly improved cross-dataset concordance. Applications to patient-derived neuroblastoma organoids and leukemia patients’ primary cells demonstrate that DRS improves replicate-level consistency in patients’ drug-response profiles. To improve reproducible pharmacogenomic studies, we make openly available an integrated Drug Response Resource (iDRR, https://aittokallio.group/iDRR/ ), a standardized 15-dataset portal that supports robust biomarker discovery and cross-study benchmarking.
- Open Access
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Open AccessMultiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.